Idiopathic Inflammatory Myopathies Clinical Trial
Official title:
Real-world Experience With Inhibitors of Janus Kinase for the Treatment of Idiopathic Inflammatory Myopathies -- a Prospective Observational Study
This study aims to explore the clinical characteristics and mechanism of inhibitors of janus kinase in the treatment of idiopathic inflammatory myopathies
The investigators designed a single center, open-label, prospective study. Adults with active idiopathic inflammatory myopathies will be enrolled, meeting the Bohan & Peter Dermatomyositis/Polymyositis(DM/PM) or Rheumatology(ACR) & European allance of associations for rheumatology(EULAR)(2017) diagnostic criteria. Inhibitors of janus kinase including tofacitinib 5 mg once a day or twice a day and baricitinib 2mg once a day or 4mg once a day was administered for 6 months to explore its efficacy and safety, which could help to evaluate inhibitors of janus kinase's clinical characteristics and mechanism. Patients would be evaluated the improvement of clinical and laboratory indexes. Changes of symptoms, immune cell subsets and cytokines were monitored. Symptoms were evaluated by Visual Analogue Scale (VAS) of patient global and physician global, manual muscle testing(MMT-8), the Health Assessment Questionnaire(HAQ), Creatine kinase, Myositis Disease Activity Assessment Tool(MDAAT). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05833711 -
Study Evaluating Efficacy and Safety of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy
|
Phase 2 | |
| Recruiting |
NCT04561557 -
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
|
Early Phase 1 | |
| Completed |
NCT04208464 -
JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIM
|
Phase 2 | |
| Completed |
NCT03267277 -
Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis
|
Phase 2/Phase 3 | |
| Recruiting |
NCT06316076 -
Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases
|
Phase 1 | |
| Not yet recruiting |
NCT06350110 -
Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05879419 -
Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases
|
Phase 4 | |
| Recruiting |
NCT04792931 -
Adult Autoimmune Myopathies (MAIA)
|
N/A | |
| Not yet recruiting |
NCT06417398 -
Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases
|
Early Phase 1 | |
| Not yet recruiting |
NCT06285539 -
Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases
|
Phase 2 | |
| Recruiting |
NCT04664465 -
PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS
|
||
| Not yet recruiting |
NCT06152172 -
CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101
|
Phase 1 | |
| Completed |
NCT03918356 -
Application of Electrical Impedance Myography (EIM) as a Potential Biomarker of Idiopathic Inflammatory Myopathies
|
N/A | |
| Completed |
NCT00341679 -
Studies of the Natural History and Pathogenesis of Autoimmune/Connective Tissue Diseases
|
||
| Recruiting |
NCT05952531 -
Characterizing Myositis With 68Ga-FAPI PET/CT
|
Early Phase 1 | |
| Recruiting |
NCT05200702 -
Assessment of Safety and Acute Effects of a Knee-hip Powered Soft Exoskeleton in Patients With Neuromuscular Disorders
|
N/A | |
| Completed |
NCT03092167 -
Physical Training in Patients With Idiopathic Inflammatory Myopathies
|
N/A | |
| Recruiting |
NCT03092180 -
Optimizing Treatment on Idiopathic Inflammatory Myopathies
|
||
| Recruiting |
NCT05199246 -
Assessment of Safety and Acute Effects of a Lower-limb Powered Dermoskeleton in Patients With Neuromuscular Disorders
|
N/A | |
| Not yet recruiting |
NCT04034199 -
Treating Idiopathic Inflammatory Myopathies Related Reduced Bone Mineral Density With Denosumab or Zoledronic Acid
|
Phase 3 |